The Royal Hospital has announced a major medical milestone by successfully localising advanced molecular testing for colorectal cancer. This development, led by the Department of Medical Laboratories and the Histology and Cytology Section, marks the first time that specific genetic tests—KRAS, NRAS, and BRAF—have been performed within the Sultanate of Oman. Previously, these essential diagnostic procedures were conducted abroad, often requiring a waiting period of more than three weeks for results to return.
The introduction of these tests locally represents a qualitative leap in precision oncology, reducing the diagnostic timeframe to just one working day. This rapid turnaround allows medical professionals to initiate targeted treatments almost immediately, significantly improving the efficiency of therapeutic decisions and the overall quality of care for cancer patients. This advancement is a key part of the Ministry of Health’s wider strategy to enhance specialised diagnostic services and promote precision medicine across the country.
Dr Mohammed al Masqari, Head of the Histology and Cytology Section, stated that this strategic move supports the national oncology treatment system by providing timely and accurate data for clinical decisions. He noted that the achievement demonstrates the high technical readiness of Oman’s medical laboratories and the expertise of national staff. This initiative aligns with the objectives of Oman Vision 2040, which seeks to localise advanced medical technologies and build a sustainable, innovation-led healthcare system.
Source:
Oman Observer
